Mar 30, 2021

VIRALEZE™ now launched by LloydsPharmacy in the UK

VIRALEZE™ now launched by LloydsPharmacy in the UK

Melbourne, Australia; 30 March 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today confirms that Starpharma’s VIRALEZE™ antiviral nasal spray has launched in the UK by LloydsPharmacy, as announced on 25 March 2021.

VIRALEZE™ is now available for purchase in the UK online at LloydsPharmacy.

Following the online launch, LloydsPharmacy plan to rollout VIRALEZE™ instore to their 1,400 UK pharmacies in April. VIRALEZE™ will also be available through a further 14,000 independent pharmacies in the UK serviced by McKesson’s AAH wholesale division.

Starpharma last week signed an exclusive sales and distribution agreement for the UK with LloydsPharmacy/McKesson. This incorporates a reciprocal exclusivity arrangement for VIRALEZE™ with significant investment in marketing by Lloyds, both online and instore.

Starpharma also plans to roll the product out across Europe, and to seek registration for the product in other regions, including Australia.

Visit www.viraleze.co for more information on VIRALEZE™.

About LloydsPharmacy

LloydsPharmacy has around 1,400 pharmacies across the UK. These are based predominantly in community and health centre locations and include over 200 LloydsPharmacy in Sainsbury’s stores. The company employs over 19,100 employees and dispenses more than 130 million prescription items annually. 

LloydsPharmacy is part of McKesson Europe AG; a leading international pharmaceutical wholesale and retail pharmacy company.  With strong brands and about 38,000 employees, McKesson Europe is active in 13 European countries.

Every day, the company serves over two million customers – at around 2,300 McKesson-owned pharmacies and at over 7,000 participants in brand partnership schemes. With more than 100 wholesale branches across Europe, we supply more than 55,000 pharmacies and hospitals every day with more than 100,000 pharmaceutical products.

McKesson Corporation, Irving, Texas, USA, is the majority shareholder in McKesson Europe AG. McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.

About VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ Antiviral Nasal Spray was developed by Starpharma (ASX: SPL) and is registered for sale in the UK and Europe. It is an easy-to-use antiviral nasal spray containing 1% w/w astodrimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus SARS-CoV-2.

VIRALEZE™ binds to and irreversibly inactivates a broad spectrum of viruses. Inactivated viruses are blocked from attaching to cells inside your nose and taking hold. In addition to providing a protective antiviral barrier, VIRALEZE™ provides a moisturising layer to help keep nasal tissue hydrated, protecting it from dryness and damage.

SPL7013 is included in products approved in >40 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

VIRALEZE™ can be used alongside vaccines, masks, and physical distancing.

 Advantages of VIRALEZE™

  • Broad-spectrum, works against multiple strains of SARS-CoV-2 and multiple viruses.
  • Potent antiviral activity against multiple strains of SARS-CoV-2.
  • Virucidal, irreversibly and rapidly inactivating >99.9% of coronavirus/ SARS‑CoV‑2 within one minute[1].
  • Ability to inactivate virus either before or after exposure.
  • Contains a well-tolerated, already marketed active which is not absorbed into the bloodstream.
  • Provides a moisturising and protective barrier to help keep nasal tissue hydrated.
  • Room temperature storage, easy and convenient for regular use.

Starpharma acknowledges the $1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.

Download ASX Announcement: VIRALEZE™ now launched by LloydsPharmacy in the UK (PDF 224kb)

[1] https://doi.org/10.1101/2020.08.20.260190

 This contains certain forward-looking statements.